JP2019510745A5 - - Google Patents

Download PDF

Info

Publication number
JP2019510745A5
JP2019510745A5 JP2018544455A JP2018544455A JP2019510745A5 JP 2019510745 A5 JP2019510745 A5 JP 2019510745A5 JP 2018544455 A JP2018544455 A JP 2018544455A JP 2018544455 A JP2018544455 A JP 2018544455A JP 2019510745 A5 JP2019510745 A5 JP 2019510745A5
Authority
JP
Japan
Prior art keywords
composition
patient
lactose
linoleic acid
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018544455A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510745A (ja
JP7125350B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/054526 external-priority patent/WO2017144725A1/en
Publication of JP2019510745A publication Critical patent/JP2019510745A/ja
Publication of JP2019510745A5 publication Critical patent/JP2019510745A5/ja
Application granted granted Critical
Publication of JP7125350B2 publication Critical patent/JP7125350B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018544455A 2016-02-26 2017-02-27 ラクトース不耐性を処置する方法 Active JP7125350B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662300376P 2016-02-26 2016-02-26
US62/300,376 2016-02-26
PCT/EP2017/054526 WO2017144725A1 (en) 2016-02-26 2017-02-27 Methods of treating lactose intolerance

Publications (3)

Publication Number Publication Date
JP2019510745A JP2019510745A (ja) 2019-04-18
JP2019510745A5 true JP2019510745A5 (enExample) 2020-04-09
JP7125350B2 JP7125350B2 (ja) 2022-08-24

Family

ID=58162625

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018544455A Active JP7125350B2 (ja) 2016-02-26 2017-02-27 ラクトース不耐性を処置する方法

Country Status (6)

Country Link
US (1) US20190046490A1 (enExample)
EP (1) EP3419616A1 (enExample)
JP (1) JP7125350B2 (enExample)
CA (1) CA3014575A1 (enExample)
MA (1) MA43682A (enExample)
WO (1) WO2017144725A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA020856B1 (ru) 2009-02-16 2015-02-27 Джулиани Интернэшнл Лимитед Способы лечения патологических состояний, связанных с волосами
JP6301844B2 (ja) 2012-02-09 2018-03-28 ノグラ ファーマ リミテッド 線維症の処置方法
EP3921299B1 (en) 2019-02-08 2024-11-20 Nogra Pharma Limited Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
ES2252874T3 (es) * 1997-12-12 2006-05-16 Purdue Research Foundation Utilizacion de acido linoleico conjugado para tratamiento de la diabetes mellitus tipo ii.
US7015249B1 (en) * 1997-12-12 2006-03-21 Purdue Research Foundation Methods and compositions for treating diabetes
WO2003043569A2 (en) * 2001-11-16 2003-05-30 Nutrition 21, Inc. Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases
EP1719543A1 (en) * 2005-05-04 2006-11-08 Asan Labs., Ltd. Use of histone deacetylase inhibitors for the treatment of gastrointestinal distress
WO2007096148A1 (en) * 2006-02-23 2007-08-30 Lipid Nutrition B.V. Immunoregulation
IE20070129A1 (en) * 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
US20090264520A1 (en) * 2008-04-21 2009-10-22 Asha Lipid Sciences, Inc. Lipid-containing compositions and methods of use thereof
ES2627745T3 (es) 2008-11-13 2017-07-31 Nogra Pharma Limited Composiciones antisentido, y procedimientos de fabricación y uso de las mismas
EP2844242A1 (en) 2012-04-18 2015-03-11 Nogra Pharma Limited Methods of treating lactose intolerance
JP6096179B2 (ja) * 2012-05-10 2017-03-15 国立大学法人岩手大学 ラクターゼ活性を有するタンパク質、該タンパク質をコードする遺伝子、該遺伝子を含有する組み換えベクター、形質転換体、及びその製造方法並びに用途
AU2014243102B2 (en) * 2013-03-26 2018-04-26 Lipid Therapeutics Gmbh Pharmaceutical formulation comprising phosphatidylcholine for the treatment of ulcerative colitis

Similar Documents

Publication Publication Date Title
JP6077857B2 (ja) β−ヒドロキシ−β−メチル酪酸塩（ＨＭＢ）の改善された投与方法
CN111227044B (zh) 一种乳制品、其制备方法及医药应用
TW200902040A (en) Probiotics in a pre-and/or post-surgical environment
EP3305083A1 (en) Lipid-containing compositions and methods of use thereof
TW200815023A (en) Prevention and treatment of otitis media
US9314444B2 (en) Composition and method for treatment of NASH
CN120131635A (zh) 包含尿石素化合物的组合物
JP2023105154A (ja) がん細胞のｐＡＭＰＫαまたはＣＯＸ－２の含有量を調節するための薬剤の調製のための増感剤の使用
US20090203780A1 (en) Use of a Polyunsaturated Fatty Acid Compound
CN1946412B (zh) 炎性肠病的预防和/或治疗剂
Gaby Alternative treatments for rheumatoid arthritis
CN110403014A (zh) 一种能抑制食欲的营养粉及其制备方法与应用
Scholz The role of nutrition in the etiology of inflammatory bowel disease
JP4603269B2 (ja) 生理活性のない高分散型基質上で乾燥させた馬乳濃縮物の使用
WO2019181822A1 (ja) エネルギー代謝促進用組成物
CN104411319A (zh) 山楂和植物甾醇类及其对代谢性疾病的作用
CN1917868B (zh) 包含l-丝氨酸、l-异亮氨酸、叶酸和痕量元素的用于治疗银屑病的组合物
JP2025500841A5 (enExample)
EP2234611A2 (en) Composition for treating sterile inflammation
JP5823695B2 (ja) 肝機能障害予防剤
Holečková et al. Effect of a 3-month nutritional intervention with a high protein omega 3-enriched oral nutritional supplement on selected anthropometric and laboratory parameters and muscle strength in oncology patients
ES2302396B1 (es) Alimento funcional a base de un producto lacteo fermentado liquido y acido linoleico conjugado.
WO2018207122A1 (en) Composition to prevent intestinal damage
KR101402456B1 (ko) 피톤치드 및 공액리놀레산을 포함하는 항비만용 조성물
William et al. Optimising Breastfeeding with Functional Foods: A Mini Review